Latest revenue
$204.9M
as of 2026-03-31
Latest net income
$19.8M
as of 2026-03-31
Net margin
9.7%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Historical multiples
How does TGTX's current valuation compare to its own past?
P/E uses year-end weekly close ÷ (net income ÷ shares outstanding today). Held shares constant at today's count, which understates the per-share earnings improvement from buybacks over the period. PEG uses 5y revenue CAGR as a proxy for EPS growth — close, but not identical (margin expansion or dilution can drive a wedge). Best read as a comparator across companies and industries, not as a precise replica of historical multiples.
Community sentiment
Where do you think TGTX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.14B
- Enterprise value
- $6.45B
- P/E (trailing)
- 13.7×
- Forward P/E
- —
- P/B
- 10.53×
- Dividend yield
- 0.0%
- 52-wk high
- $44.65
- 52-wk low
- $25.28
- Beta
- —
- Shares out
- 153.1M
5-year trend
What this company does
ITEM 1. BUSINESS. OVERVIEW TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined…
AI summary unavailable — showing raw filing excerpt
Generated from TGTX's filing dated 2026-02-27
Key risks
ITEM 1A. RISK FACTORS. You should carefully consider the following risk factors and the other information contained elsewhere in this Annual Report on Form 10-K before making an investment in our securities. If any of the following risks occur, our business, financial condition or operating results could be materially harmed. An investment in our securities is speculative in nature, involves a high degree of risk, and should not be made by an investor who cannot bear the economic risk of its investment for an indefinite period of time and who cannot afford the loss of its entire investment. The risks described below are not the only ones that our business faces. Additional risks not…
AI summary unavailable — showing raw filing excerpt
Generated from TGTX's filing dated 2026-02-27
Profitability
Operating margin
20.0%
57.0%Net margin
72.6%
920.9%Return on equity
69.0%
556.2%Return on assets
42.1%
939.1%Leverage
Debt / equity
0.64×
59.9%Long-term debt / equity
0.38×
65.5%Debt / assets
39.1%
36.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $204.9M | +69.6% | $19.8M | +290.8% | 9.7% |
Q4 2025 2025-12-31 | $192.6M | +78.0% | $23.0M | -39.2% | 12.0% |
Q3 2025 2025-09-30 | $161.7M | +92.8% | $390.9M | +751621.2% | 241.7% |
Q2 2025 2025-06-30 | $141.1M | +92.1% | $28.2M | +836.3% | 20.0% |
Q1 2025 2025-03-31 | $120.9M | +90.4% | $5.1M | +147.3% | 4.2% |
Q4 2024 2024-12-31 | $108.2M | — | $37.9M | — | 35.0% |
Q3 2024 2024-09-30 | $83.9M | -49.4% | $52.0K | -99.8% | 0.1% |
Q2 2024 2024-06-30 | $73.5M | +357.0% | $-3.8M | +92.0% | -5.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on TGTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.2M
Net activity
−$1.2M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-11-24 | Yann Echelard Director | Sale | 5,000 | $32.57 | $162.8K | |
| 2025-09-11 | Sagar Lonial Director | Sale | 20,852 | $32.24 | $672.3K | |
| 2025-06-13 | Yann Echelard Director | Sale | 10,000 | $36.94 | $369.4K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns TGTX
Institutional value
$2.10B
Total shares held
64.1M
Distinct holders
229
-119 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 22.3M | $739.2M | +404.5K (+1.9%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8.3M | $274.9M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 6.6M | $219.4M | — | New |
| 4 | Clearbridge Investments, LLC | 3.2M | $106.7M | -237.1K (-6.9%) | Trimmed |
| 5 | CONGRESS ASSET MANAGEMENT CO | 2.2M | $72.0M | +245.7K (+12.8%) | Added |
| 6 | JANE STREET GROUP, LLC | 2.0M | $67.8M | +1.1M (+110.5%) | Added |
| 7 | Pictet Asset Management Holding SA | 1.7M | $58.0M | +286.3K (+19.6%) | Added |
| 8 | Nuveen, LLC | 1.4M | $48.1M | +493.9K (+51.8%) | Added |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $36.0M | +612.1K (+129.5%) | Added |
| 10 | VANGUARD FIDUCIARY TRUST CO | 968.7K | $32.2M | — | New |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 957.0K | $31.8M | +273.4K (+40.0%) | Added |
| 12 | Bank of New York Mellon Corp | 887.3K | $29.5M | -11.1K (-1.2%) | Trimmed |
| 13 | Invesco Ltd. | 720.9K | $23.9M | -888.9K (-55.2%) | Trimmed |
| 14 | PRINCIPAL FINANCIAL GROUP INC | 665.5K | $22.1M | -182.3K (-21.5%) | Trimmed |
| 15 | Penn Capital Management Company, LLC | 542.0K | $18.0M | +3.8K (+0.7%) | Added |
| 16 | BANK OF MONTREAL /CAN/ | 515.3K | $17.1M | +3.0K (+0.6%) | Added |
| 17 | Assenagon Asset Management S.A. | 510.1K | $16.9M | +349.7K (+218.0%) | Added |
| 18 | UBS Group AG | 505.6K | $16.8M | -31.4K (-5.8%) | Trimmed |
| 19 | Public Sector Pension Investment Board | 487.3K | $16.2M | +17.0K (+3.6%) | Added |
| 20 | Voya Investment Management LLC | 419.6K | $13.9M | +14.7K (+3.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once TGTX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.